INPP5D (inositol polyphosphate-5-phosphatase D), also known as SHIP1 (Src homology 2 domain-containing inositol phosphatase 1), is a lipid phosphatase encoded by the INPP5D gene. It regulates cellular signaling by hydrolyzing phosphatidylinositol (3.4.5)-trisphosphate [PI(3.4.5)P3] to PI(3.4)P2. thereby modulating phosphoinositide-dependent signaling pathways. SHIP1 is predominantly expressed in hematopoietic cells, including macrophages, dendritic cells, mast cells, and B cells, where it acts as a negative regulator of immune receptor signaling (e.g., B cell receptors, Fc receptors) and cytokine responses. Its activity influences immune cell activation, proliferation, and survival, making it a critical player in immune homeostasis and inflammatory diseases.
INPP5D antibodies are essential tools for studying SHIP1 expression, localization, and function in both physiological and pathological contexts. These antibodies are widely used in techniques like Western blotting, immunohistochemistry, flow cytometry, and immunoprecipitation to investigate SHIP1's role in immune regulation, cancer (e.g., leukemia, lymphoma), and neurodegenerative disorders like Alzheimer’s disease, where microglial SHIP1 has been implicated. Commercially available antibodies target specific epitopes or isoforms, with validation often including knockout controls to ensure specificity. Research involving INPP5D antibodies continues to uncover its therapeutic potential, particularly in targeting immune dysregulation or oncogenic signaling pathways.